Revenue rose 8.3% year over year to $951.7M in 2026Q3 while operating margin reached 21.9% and gross margin recovered to 45.1%, though gains may partly reflect favorable timing.
IDEX Corporation (IEX) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Sales/Revenue | 3.66B | 3.46B | 3.27B | 3.27B | 3.18B | 2.76B | 2.35B | 2.49B | 2.48B | 2.29B | 2.11B | 2.02B | 2.15B | 2.02B | 1.95B | 1.84B | 1.51B | 1.33B | 1.49B | 1.36B | 1.15B | 1.04B | 928.3M | 797.92M | 742.01M | 726.95M | 704.28M | 655M | 640.1M | 552.2M | 562.6M |
| Revenue Growth % | 6.93% | 5.77% | -0.16% | 2.89% | 15.09% | 17.57% | -5.73% | 0.44% | 8.58% | 8.25% | 4.57% | -5.92% | 6.11% | 3.58% | 6.3% | 21.5% | 13.79% | -10.73% | 9.63% | 17.64% | 10.7% | 12.39% | 16.34% | 7.53% | 2.07% | 3.22% | 7.52% | 2.33% | 15.92% | -1.85% | 15.45% |
| Cost of Goods Sold | 2.02B | 1.92B | 1.75B | 1.65B | 1.59B | 1.4B | 1.19B | 1.22B | 1.32B | 1.22B | 1.13B | 1.08B | 1.16B | 1.12B | 1.11B | 1.05B | 862.79M | 777.67M | 862.54M | 762.08M | 652.73M | 573.49M | 536.26M | 488.6M | 460.58M | 463.23M | 401.42M | 375.1M | 364.5M | 313.1M | 329.5M |
| COGS % of Revenue | - | 55.49% | 53.6% | 50.43% | 49.89% | 50.76% | 50.76% | 48.94% | 53.06% | 53.26% | 53.39% | 53.42% | 54.03% | 55.13% | 57.01% | 56.95% | 57.02% | 58.49% | 57.91% | 56.09% | 56.52% | 54.97% | 57.77% | 61.23% | 62.07% | 63.72% | 57% | 57.27% | 56.94% | 56.7% | 58.57% |
| Gross Profit | 1.64B | 1.54B | 1.52B | 1.62B | 1.59B | 1.36B | 1.16B | 1.27B | 1.17B | 1.07B | 984.87M | 941.32M | 987.41M | 908.16M | 840.1M | 791.35M | 650.16M | 551.09M | 626.95M | 596.55M | 502.21M | 437.77M | 392.04M | 309.32M | 281.44M | 263.72M | 302.86M | 279.9M | 275.6M | 239.1M | 233.1M |
| Gross Margin % | 44.87% | 44.51% | 46.4% | 49.57% | 50.11% | 49.24% | 49.24% | 51.06% | 46.94% | 46.74% | 46.61% | 46.58% | 45.97% | 44.87% | 42.99% | 43.04% | 42.97% | 41.45% | 42.09% | 43.91% | 43.48% | 41.96% | 42.23% | 38.77% | 37.93% | 36.28% | 43% | 42.73% | 43.06% | 43.3% | 41.43% |
| Gross Profit Growth % | - | 1.46% | -6.54% | 1.78% | 17.11% | 17.58% | -9.1% | 9.26% | 9.06% | 8.55% | 4.63% | -4.67% | 8.73% | 8.1% | 6.16% | 21.72% | 17.98% | -12.1% | 5.1% | 18.79% | 14.72% | 11.66% | 26.74% | 9.91% | 6.72% | -12.92% | 8.2% | 1.56% | 15.27% | 2.57% | 16.09% |
| Operating Expenses | 875.2M | 818.8M | 819.8M | 872.1M | 804.9M | 707.5M | 621.13M | 672.09M | 581.72M | 566.04M | 533.69M | 510.41M | 539.52M | 509.45M | 480.89M | 451.9M | 390.07M | 355.05M | 372.89M | 341.47M | 285M | 256.74M | 242.65M | 199.46M | 181.27M | 179.06M | 186.34M | 175.3M | 166.1M | 135.5M | 134.7M |
| OpEx % of Revenue | - | 23.68% | 25.08% | 26.64% | 25.3% | 25.59% | 26.41% | 26.94% | 23.42% | 24.75% | 25.26% | 25.26% | 25.12% | 25.17% | 24.61% | 24.58% | 25.78% | 26.7% | 25.04% | 25.13% | 24.68% | 24.61% | 26.14% | 25% | 24.43% | 24.63% | 26.46% | 26.76% | 25.95% | 24.54% | 23.94% |
| Selling, General & Admin | 861.6M | 818.8M | 749M | 696.2M | 648.1M | 573.2M | 490.63M | 523.29M | 533.72M | 523.64M | 494.29M | 476.81M | 502.72M | 476.45M | 444.49M | 415.9M | 358.27M | 325.45M | 343.39M | 313.37M | 260.2M | 232.94M | 221.41M | 199.46M | 181.27M | 164.89M | 149.64M | 140.5M | 132.6M | 110.6M | 111.5M |
| SG&A % of Revenue | - | 23.68% | 22.91% | 21.27% | 20.37% | 20.73% | 20.86% | 20.98% | 21.49% | 22.89% | 23.39% | 23.6% | 23.41% | 23.54% | 22.74% | 22.62% | 23.68% | 24.48% | 23.05% | 23.06% | 22.53% | 22.33% | 23.85% | 25% | 24.43% | 22.68% | 21.25% | 21.45% | 20.72% | 20.03% | 19.82% |
| Research & Development | 0 | 0 | 178.6M | 175.9M | 156.8M | 133M | 130.5M | 148.8M | 48M | 42.4M | 39.4M | 33.6M | 36.8M | 33M | 36.4M | 36M | 31.8M | 29.6M | 29.5M | 28.1M | 24.8M | 23.8M | 21.24M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | 5.46% | 5.37% | 4.93% | 4.81% | 5.55% | 5.96% | 1.93% | 1.85% | 1.86% | 1.66% | 1.71% | 1.63% | 1.86% | 1.96% | 2.1% | 2.23% | 1.98% | 2.07% | 2.15% | 2.28% | 2.29% | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 3M | 0 | -107.8M | 0 | 0 | 1.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.16M | 36.7M | 34.8M | 33.5M | 24.9M | 23.2M |
| Operating Income | 766.3M | 720M | 696.9M | 750.7M | 789.5M | 654M | 536.79M | 601.75M | 584.17M | 503.04M | 451.17M | 430.91M | 447.9M | 398.71M | 359.21M | 339.44M | 260.08M | 196.03M | 254.06M | 255.08M | 217.21M | 181.03M | 149.38M | 109.86M | 100.37M | 73.44M | 116.52M | 104.6M | 109.5M | 103.6M | 98.4M |
| Operating Margin % | 20.95% | 20.82% | 21.32% | 22.93% | 24.81% | 23.65% | 22.83% | 24.12% | 23.52% | 21.99% | 21.35% | 21.32% | 20.85% | 19.7% | 18.38% | 18.46% | 17.19% | 14.74% | 17.06% | 18.77% | 18.81% | 17.35% | 16.09% | 13.77% | 13.53% | 10.1% | 16.54% | 15.97% | 17.11% | 18.76% | 17.49% |
| Operating Income Growth % | - | 3.31% | -7.17% | -4.91% | 20.72% | 21.84% | -10.79% | 3.01% | 16.13% | 11.5% | 4.7% | -3.79% | 12.34% | 11% | 5.82% | 30.51% | 32.67% | -22.84% | -0.4% | 17.44% | 19.98% | 21.19% | 35.97% | 9.45% | 36.68% | -36.97% | 11.39% | -4.47% | 5.7% | 5.28% | 14.15% |
| EBITDA | 980.3M | 926.5M | 872.5M | 902.8M | 909.2M | 757M | 620.29M | 678.65M | 661.72M | 587.25M | 538.07M | 509.03M | 524.8M | 478.05M | 437.52M | 411.83M | 318.19M | 252.38M | 302.66M | 293.58M | 247.62M | 211.68M | 180.91M | 139.92M | 130.48M | 117.73M | 153.22M | 139.4M | 143M | 128.5M | 121.6M |
| EBITDA Margin % | 26.8% | 26.8% | 26.69% | 27.58% | 28.57% | 27.38% | 26.38% | 27.2% | 26.64% | 25.67% | 25.46% | 25.19% | 24.43% | 23.62% | 22.39% | 22.4% | 21.03% | 18.98% | 20.32% | 21.61% | 21.44% | 20.29% | 19.49% | 17.54% | 17.58% | 16.2% | 21.76% | 21.28% | 22.34% | 23.27% | 21.61% |
| EBITDA Growth % | 7.7% | 6.19% | -3.36% | -0.7% | 20.11% | 22.04% | -8.6% | 2.56% | 12.68% | 9.14% | 5.7% | -3.01% | 9.78% | 9.26% | 6.24% | 29.43% | 26.08% | -16.61% | 3.09% | 18.56% | 16.98% | 17.01% | 29.3% | 7.23% | 10.82% | -23.16% | 9.91% | -2.52% | 11.28% | 5.67% | 17.72% |
| D&A (Non-Cash Add-back) | 214M | 206.5M | 175.6M | 152.1M | 119.7M | 103M | 83.5M | 76.9M | 77.54M | 84.22M | 86.89M | 78.12M | 76.91M | 79.33M | 78.31M | 72.39M | 58.11M | 56.35M | 48.6M | 38.5M | 30.41M | 30.65M | 31.53M | 30.05M | 30.11M | 44.3M | 36.7M | 34.8M | 33.5M | 24.9M | 23.2M |
| EBIT | 766.2M | 697M | 683.8M | 812M | 790.1M | 617.5M | 521.11M | 570.92M | 579.55M | 506.82M | 420.98M | 426.95M | 427.11M | 387.9M | 120.82M | 297.02M | 239.22M | 177.89M | 211.43M | 258.52M | 218.25M | 181.59M | 148.64M | 109.86M | 100.17M | 84.66M | 116.52M | 104.6M | 109.5M | 103.6M | 87.7M |
| Net Interest Income | -62.7M | -64.4M | -44.5M | -51.7M | -40.7M | -37.7M | -50.77M | -38.01M | -50.61M | -51.54M | -52.47M | -34.61M | -34.67M | -34.78M | -34.61M | -23.14M | -7.34M | -9.07M | -19.2M | -23.35M | -16.35M | -14.37M | -14.76M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 62.7M | 64.4M | 44.5M | 51.7M | 40.7M | 37.7M | 50.77M | 38.01M | 50.61M | 51.54M | 52.47M | 34.61M | 34.67M | 34.78M | 34.61M | 23.14M | 7.34M | 9.07M | 19.2M | 23.35M | 16.35M | 14.37M | 14.76M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -62.8M | -87.4M | -57.6M | 9.6M | -40.1M | -74.2M | -66.45M | -68.84M | -55.23M | -47.77M | -82.66M | -38.56M | -55.46M | -45.58M | -273.01M | -65.56M | -28.21M | -27.21M | -61.83M | -19.92M | -15.31M | -13.81M | -15.51M | -13.19M | -16.48M | -20.01M | -15.49M | -17.4M | -21.8M | -19.1M | -8.8M |
| Pretax Income | 703.5M | 632.6M | 639.3M | 760.3M | 749.4M | 579.8M | 470.34M | 532.9M | 528.94M | 455.27M | 368.51M | 392.35M | 392.44M | 353.13M | 86.2M | 273.88M | 231.87M | 168.83M | 198.7M | 235.16M | 201.89M | 168.93M | 133.88M | 96.67M | 83.89M | 53.43M | 101.03M | 87.2M | 87.7M | 84.5M | 78.9M |
| Pretax Margin % | 19.23% | 18.3% | 19.56% | 23.22% | 23.55% | 20.97% | 20% | 21.36% | 21.3% | 19.9% | 17.44% | 19.42% | 18.27% | 17.45% | 4.41% | 14.9% | 15.32% | 12.7% | 13.34% | 17.31% | 17.48% | 16.19% | 14.42% | 12.12% | 11.31% | 7.35% | 14.34% | 13.31% | 13.7% | 15.3% | 14.02% |
| Income Tax | 167.9M | 150.1M | 134.7M | 164.7M | 162.7M | 130.5M | 92.56M | 107.38M | 118.37M | 118.02M | 97.4M | 109.54M | 113.05M | 97.91M | 48.57M | 80.02M | 74.77M | 55.44M | 67.34M | 79.3M | 68.17M | 59.13M | 47.47M | 34.32M | 29.78M | 20.72M | 37.58M | 32.8M | 33.3M | 31M | 28.7M |
| Effective Tax Rate % | 23.87% | 23.73% | 21.07% | 21.66% | 21.71% | 22.51% | 19.68% | 20.15% | 22.38% | 25.92% | 26.43% | 27.92% | 28.81% | 27.73% | 56.35% | 29.22% | 32.25% | 32.84% | 33.89% | 33.72% | 33.77% | 35% | 35.46% | 35.5% | 35.5% | 38.78% | 37.2% | 37.61% | 37.97% | 36.69% | 36.38% |
| Net Income | 535.8M | 483.2M | 505M | 596.1M | 586.9M | 449.4M | 377.8M | 425.52M | 410.57M | 337.26M | 271.11M | 282.81M | 279.39M | 255.22M | 37.63M | 193.86M | 157.1M | 113.39M | 131.36M | 155.15M | 146.67M | 109.8M | 86.41M | 62.35M | 54.11M | 32.71M | 63.45M | 54.4M | 64.6M | 58.7M | 50.2M |
| Net Margin % | 14.65% | 13.98% | 15.45% | 18.21% | 18.45% | 16.25% | 16.07% | 17.06% | 16.53% | 14.74% | 12.83% | 14% | 13.01% | 12.61% | 1.93% | 10.54% | 10.38% | 8.53% | 8.82% | 11.42% | 12.7% | 10.52% | 9.31% | 7.81% | 7.29% | 4.5% | 9.01% | 8.31% | 10.09% | 10.63% | 8.92% |
| Net Income Growth % | 12.07% | -4.32% | -15.28% | 1.57% | 30.6% | 18.95% | -11.21% | 3.64% | 21.74% | 24.4% | -4.14% | 1.22% | 9.47% | 578.22% | -80.59% | 23.4% | 38.55% | -13.68% | -15.33% | 5.78% | 33.58% | 27.08% | 38.58% | 15.23% | 65.43% | -48.44% | 16.63% | -15.79% | 10.05% | 16.93% | 10.82% |
| Net Income (Continuing) | 535.6M | 482.5M | 504.6M | 595.6M | 586.7M | 449.3M | 377.78M | 425.52M | 410.57M | 337.26M | 271.11M | 282.81M | 279.39M | 255.22M | 37.63M | 193.86M | 157.1M | 113.39M | 127.03M | 155.86M | 133.72M | 108.58M | 86.41M | 62.35M | 54.11M | 32.71M | 63.45M | 54.4M | 54.4M | 53.5M | 44.4M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -1.5M | -1.3M | -600K | -200K | 300K | 0 | 123K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 7.24 | 6.41 | 6.64 | 7.85 | 7.72 | 5.88 | 4.94 | 5.57 | 5.29 | 4.36 | 3.53 | 3.62 | 3.45 | 3.09 | 0.45 | 2.32 | 1.90 | 1.40 | 1.53 | 1.89 | 1.81 | 1.39 | 1.12 | 0.83 | 0.74 | 0.47 | 0.92 | 0.80 | 0.92 | 0.87 | 0.75 |
| EPS Growth % | 13.92% | -3.46% | -15.41% | 1.68% | 31.29% | 19.03% | -11.31% | 5.29% | 21.33% | 23.51% | -2.49% | 4.93% | 11.65% | 586.67% | -80.6% | 22.11% | 35.71% | -8.5% | -19.05% | 4.42% | 30.22% | 24.11% | 34.94% | 12.16% | 57.45% | -48.91% | 15% | -13.04% | 5.75% | 16% | 10.29% |
| EPS (Basic) | - | 6.41 | 6.67 | 7.88 | 7.75 | 5.91 | 4.99 | 5.63 | 5.37 | 4.41 | 3.57 | 3.65 | 3.48 | 3.11 | 0.45 | 2.34 | 1.93 | 1.41 | 1.55 | 1.92 | 1.84 | 1.43 | 1.15 | 0.85 | 0.76 | 0.48 | 0.95 | 0.82 | 0.94 | 0.89 | 0.77 |
| Diluted Shares Outstanding | 74M | 75.3M | 75.9M | 75.9M | 76M | 76.4M | 76.4M | 76.45M | 77.56M | 77.33M | 76.76M | 77.97M | 80.73M | 82.49M | 83.64M | 83.54M | 81.98M | 80.73M | 82.32M | 82.09M | 80.98M | 79.08M | 77.02M | 74.96M | 73.09M | 69.86M | 68.92M | 67.69M | 67.62M | 67.66M | 66.77M |
| Basic Shares Outstanding | 73.7M | 75.3M | 75.7M | 75.6M | 75.7M | 76M | 75.74M | 75.59M | 76.41M | 76.23M | 75.8M | 77.13M | 79.72M | 81.52M | 82.69M | 82.14M | 80.47M | 79.72M | 81.12M | 80.67M | 79.53M | 77.09M | 75.11M | 73.19M | 71.26M | 68M | 66.88M | 66.47M | 66M | 65.64M | 64.85M |
| Dividend Payout Ratio | - | 44% | 40.65% | 31.99% | 30.23% | 35.85% | 40.18% | 34.59% | 31.05% | 32.96% | 37.86% | 34.01% | 30.68% | 28.57% | 170.31% | 28.17% | 29.49% | 34.07% | 29.99% | 24.02% | 20.72% | 22.48% | 24.78% | 29.32% | 32.75% | 52.16% | 26.45% | 30.33% | 24.46% | 23.85% | 24.5% |
Quick answers to the most common questions about buying IEX stock.
For fiscal year 2025, IDEX Corporation (IEX) reported total revenue of $3.46B. This represents a 514.6% increase compared to $562.6M in 1996.
IDEX Corporation (IEX) is profitable, generating $483.2M in net income for the fiscal year ending 2025 with a net profit margin of 14.0%.
IDEX Corporation (IEX) reported an operating income of $720.0M, resulting in an operating profit margin of 20.8%. This margin reflects the operational efficiency of the business before interest and taxes.
IDEX Corporation (IEX) generated $1.54B in gross profit for the year, representing a gross profit margin of 44.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Biopharma demand volatility in HST
Metrics are mathematically derived from official filings.
Revenue Reaccelerating Toward Mid-Single-Digit Growth
Based on reported quarterly figures, IEX's revenue rose 8.3% year over year to $951.7M in 2026Q3, up from a 1.7% gain in 2025Q1, suggesting a meaningful reacceleration in top-line momentum over the past six quarters.
The shift from low-single-digit growth in early 2025 to high-single-digit growth in the most recent quarter suggests demand is broadening rather than resting on a single segment. The reported figures do not isolate volume, pricing, or acquisition contributions, so the durability of this acceleration cannot be fully separated from M&A or currency effects. Investors should monitor whether organic growth holds at this level once the comparison base becomes less favorable.
Gross Margin Recovery Driven by Mix
As reported in the quarterly income statements, IEX's gross margin moved from 38.8% in 2024Q4 to 45.1% in 2026Q3, a recovery that appears to reflect pricing realization and a more favorable segment mix.
A roughly six-point gross margin recovery over eight quarters is substantial for an industrial manufacturer and suggests the business retains meaningful pricing power in its niche markets. The margin band between 43% and 46% over most recent quarters points to a more stable structural level than the 2024Q4 trough. Whether this level holds will depend on input cost trends in specialized metals and polymers, which the provided data does not break out.
Operating Leverage Limited by Flat SG&A
Based on the reported figures, IEX's operating margin reached 21.9% in 2026Q3 while SG&A held near $218M, indicating that incremental gross profit is flowing through to operating income at a healthy rate.
Operating income of $208.0M on gross profit of $429.5M implies that a large share of gross profit growth is converting to operating earnings, consistent with disciplined overhead control. SG&A has remained within a narrow range in recent quarters, which suggests cost discipline rather than heavy reinvestment in the sales base. The operating margin trajectory is encouraging, though the provided data does not show a clean separation between structural efficiency and timing effects.
EPS Growth Outpacing Net Income Volatility
According to reported quarterly results, IEX's diluted EPS grew 14.7% year over year in 2026Q3 to $1.95, while net margin of 15.1% reflects a relatively steady earnings conversion from operating income.
EPS growth in recent quarters has been uneven, including a sharp decline in 2024Q3 and a rebound in 2026Q1, which points to sensitivity to below-the-line items or share count changes. Stock-based compensation remains modest relative to revenue, lowering concern about dilution-driven earnings quality. The provided data does not detail tax rate or non-operating items, so those components cannot be fully assessed and warrant further investigation.
Cost of Goods Sold Scaling Below Revenue
As reported in the financial statements, IEX's COGS equaled 54.9% of revenue in 2026Q3, compared with roughly 61% in 2024Q4, suggesting improved input cost absorption as volumes and pricing evolved.
The compression of cost of goods sold as a share of revenue points to better pricing or procurement outcomes rather than a simple volume effect. R&D is not separately reported in the supplied data, so the company's investment intensity in its life sciences exposure cannot be benchmarked. Management's expense discipline appears evident in stable SG&A, though sustained gains will depend on whether specialized material costs remain contained.
Late 2024 Margin Trough as Inflection Point
Based on IEX's reported figures, gross margin fell to 38.8% in 2024Q4 before recovering above 44% by 2025Q3, marking the most significant operational inflection in the ten-quarter history.
The sharp dip in gross margin during late 2024, paired with a 2024Q4 EPS figure that still grew year over year, suggests a transitory cost or mix shock rather than a structural break. The subsequent recovery to the mid-40s range implies the company restored pricing and cost alignment within several quarters. Investors should monitor whether this recovery reflects durable operating improvements or a favorable comparison against an unusually weak base.
Margin Gains May Prove Cyclical
The strongest counter-view holds that IEX's recent gross margin expansion may reflect favorable timing rather than durable structure, with the sequential EPS guidance decline suggesting momentum may be peaking.
Revenue growth of 8.3% paired with a 14.7% EPS increase in 2026Q3 may overstate underlying trends if SG&A leverage or gross margin gains reflect timing effects. Sequential softness implied by forward guidance could signal that the recent margin peak is already behind the company. Investors should monitor whether gross margins can sustain the mid-40s range if biopharma demand softens or input costs rise.